DK0572542T3 - Fremgangsmåde til behandling af systemisk lupus erythematosus - Google Patents

Fremgangsmåde til behandling af systemisk lupus erythematosus

Info

Publication number
DK0572542T3
DK0572542T3 DK92907399T DK92907399T DK0572542T3 DK 0572542 T3 DK0572542 T3 DK 0572542T3 DK 92907399 T DK92907399 T DK 92907399T DK 92907399 T DK92907399 T DK 92907399T DK 0572542 T3 DK0572542 T3 DK 0572542T3
Authority
DK
Denmark
Prior art keywords
lupus erythematosus
systemic lupus
treating systemic
treating
intrabronchially
Prior art date
Application number
DK92907399T
Other languages
Danish (da)
English (en)
Inventor
Linda Marie Warner
Laurel Moore Adams
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0572542T3 publication Critical patent/DK0572542T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
DK92907399T 1991-02-22 1992-02-21 Fremgangsmåde til behandling af systemisk lupus erythematosus DK0572542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/660,470 US5078999A (en) 1991-02-22 1991-02-22 Method of treating systemic lupus erythematosus
PCT/US1992/001399 WO1992014477A1 (en) 1991-02-22 1992-02-21 Method of treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
DK0572542T3 true DK0572542T3 (da) 2001-09-17

Family

ID=24649665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907399T DK0572542T3 (da) 1991-02-22 1992-02-21 Fremgangsmåde til behandling af systemisk lupus erythematosus

Country Status (21)

Country Link
US (1) US5078999A (xx)
EP (1) EP0572542B9 (xx)
KR (1) KR100201517B1 (xx)
AT (1) ATE202938T1 (xx)
AU (1) AU664545B2 (xx)
CA (1) CA2103568A1 (xx)
CY (1) CY2305B1 (xx)
DE (1) DE69231927T2 (xx)
DK (1) DK0572542T3 (xx)
ES (1) ES2157901T3 (xx)
GR (1) GR3036477T3 (xx)
HK (1) HK1011281A1 (xx)
HU (1) HUT70489A (xx)
IE (1) IE920556A1 (xx)
IL (1) IL100904A (xx)
MX (1) MX9200727A (xx)
NZ (1) NZ241671A (xx)
PT (1) PT100145B (xx)
SG (1) SG52404A1 (xx)
WO (1) WO1992014477A1 (xx)
ZA (1) ZA921210B (xx)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
DE69302945T2 (de) 1992-03-27 1996-10-10 American Home Prod 29-Demethoxyrapamycin zur Induktion der Immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
JPH08509499A (ja) 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
MXPA04001524A (es) 2001-08-22 2004-05-31 Wyeth Corp 29-enoles de rapamicina.
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DK1615640T3 (da) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastiske sammensætninger
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
JP2007532655A (ja) * 2004-04-14 2007-11-15 ワイス ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン４２−エステルおよびジカルボン酸とのｆｋ−５０６３２−エステルの調製プロセス
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
JP5709354B2 (ja) 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) * 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
JP2010501499A (ja) * 2006-08-22 2010-01-21 ノバルティス アクチエンゲゼルシャフト 線維症の処置
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP2012504654A (ja) * 2008-10-03 2012-02-23 エリクシアー メディカル コーポレイション 多環状ラクトン化合物およびその使用方法
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体

Also Published As

Publication number Publication date
ZA921210B (en) 1993-08-19
PT100145B (pt) 1999-06-30
KR100201517B1 (ko) 1999-06-15
ES2157901T3 (es) 2001-09-01
EP0572542A1 (en) 1993-12-08
ATE202938T1 (de) 2001-07-15
EP0572542B1 (en) 2001-07-11
HK1011281A1 (en) 1999-07-09
AU1469192A (en) 1992-09-15
EP0572542B9 (en) 2001-11-21
SG52404A1 (en) 1998-09-28
NZ241671A (en) 1997-06-24
GR3036477T3 (en) 2001-11-30
IE920556A1 (en) 1992-08-26
IL100904A (en) 1995-10-31
HUT70489A (en) 1995-10-30
CA2103568A1 (en) 1992-08-23
WO1992014477A1 (en) 1992-09-03
DE69231927D1 (de) 2001-08-16
KR930703001A (ko) 1993-11-29
EP0572542A4 (en) 1994-06-01
AU664545B2 (en) 1995-11-23
IL100904A0 (en) 1992-11-15
PT100145A (pt) 1993-08-31
MX9200727A (es) 1992-09-01
CY2305B1 (en) 2003-07-04
US5078999A (en) 1992-01-07
DE69231927T2 (de) 2001-11-22

Similar Documents

Publication Publication Date Title
DK0572542T3 (da) Fremgangsmåde til behandling af systemisk lupus erythematosus
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
DK0817760T3 (da) Fremgangsmåde til stabillisering af slam
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
TR199701461A3 (tr) Firin tesisatindan çikan atik gazlarin imha edilmesi yöntemi.
ES1036100Y (es) Guia de extraccion para cajon.
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
PT1322701E (pt) Composicao que retarda a pre-vulcanizacao
TR200001459T2 (tr) Malzeme sathında plazma polimerizasyonu.
BR9505808A (pt) Método de controlar um aparelho de impressào eletrostatográfica
TW207954B (en) Use of rapamycin in nephrotic syndrome
DK0771786T3 (da) Fremstilling af aryl- og vinylnitriler
KR950003863U (ko) 배수구용 에프.아르.피.(f.r.p.) 자동문비
FR2714162B1 (fr) Dispositif de visée intégrant une voie épiscopique.
FI981547A (fi) Haulikon lisälaite
ES1034695Y (es) Dispositivo de fijacion de los ladrillos refrectarios que revisten una chimenea industrial.
KR970038426A (ko) 토너커버의 축받이 구조
IT1278089B1 (it) Malta per riparazioni.
BR7301593U (pt) Protetor permanente para teclado de microcomputador
ES1034403Y (es) Regla de albañileria perfeccionada.
DK1380582T3 (da) FSH-mimetika til behandling af infertilitet
DK15693D0 (da) Fremgangsmaade til stabilisering af affald
KR970052952U (ko) Hvps의 입력 바이어스 회로
IT9022134A0 (it) Dispositivo per la protezione di chiavi contro la copiatura.
DK0864032T3 (da) Fremgangsmåde til behandling af en underjordisk formation